This is important for people with Type 2 diabetes and obesity
In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)
The medicine is ready to inject
Understanding your genetic predispositions helps your provider personalize your treatment plan to maximize cardiovascular protection
Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks
Patient progress may reflect an individualized combination of medical evaluation, nutrition guidance, activity planning, behavioral support, ongoing monitoring, and clinically appropriate treatment